Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Takeda Pharmaceutical Co Ltd ADR(TAK)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for TAK
10/28/2026: TAK (3-star) is a STRONG-BUY. BUY for 81 days. Simulated Profits (21.39%). Updated daily EoD!
Takeda Pharmaceutical is a prominent global biopharmaceutical company specializing in gastroenterology, rare diseases, and plasma-derived therapies. The company has a leading position in several high-need therapeutic areas, supported by a broad, diversified product portfolio. Its recent growth strategy is defined by the integration of the Shire acquisition and a pivot toward organic R&D-driven innovation. However, investors should monitor significant debt levels, patent expiration risks, and evolving global pricing regulations that could impact margins. The stock may suit value-oriented and dividend-seeking investors who prefer established, defensive pharma players while waiting for the long-term potential of the current drug pipeline to materialize.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Takeda's growth is tied to successful R&D pipeline execution rather than aggressive market expansion. |
| Momentum investor | Weak fit | The stock historically exhibits lower volatility and tends not to experience sustained rapid momentum upturns. |
| Value investor | Strong fit | Takeda often trades at valuation multiples that reflect its mature portfolio and steady cash flows. |
| Dividend investor | Strong fit | The company has a track record of consistent dividend payments that appeal to income-oriented investors. |
| Low-risk investor | Mixed fit | While established, the pharmaceutical industry carries inherent risks regarding regulatory approvals and patent cliffs. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium | Pharmaceutical stocks can react sharply to clinical trial results or regulatory decisions. |
| Valuation risk | Low | Takeda is generally considered to be reasonably priced relative to its long-term cash flow potential. |
| Competition risk (Generic/Biosimilar) | High | Loss of patent exclusivity for key products like Entyvio or Vyvanse could materially impact revenue. |
| Business quality | Strong | Takeda possesses a robust global platform and a long history of pharmaceutical development. |
| Dividend income | Medium | While dividends are prioritized, they remain subject to the company's deleveraging and capital allocation strategies. |
| Execution risk | Medium | Successfully integrating large acquisitions and managing a global supply chain is complex. |
Price Behavior
Steady Uptrend
The stock demonstrates consistent and steady upward price momentum.
Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type Stock | Historic Profit 14.35% | Avg. Invested days 37 | Today’s Advisory Strong Buy |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 64.75B USD | Price to earnings Ratio - | 1Y Target Price 22.62 |
Price to earnings Ratio - | 1Y Target Price 22.62 | ||
Volume (30-day avg) 2.7M shares | Beta 0.1 | 52 Weeks Range 12.50 - 20.55 | Updated Date 10/28/2026 |
52 Weeks Range 12.50 - 20.55 | Updated Date 10/28/2026 | ||
Dividends yield (FY) 3.02% | Basic EPS (TTM) -0.34 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Gastroenterology | Includes Entyvio and other treatments for GI conditions. | This is a primary revenue driver that relies on long-term clinical efficacy in chronic patient populations. |
| Rare Diseases & Plasma Therapies | Includes hematology, immunology, and metabolic disease treatments. | These high-barrier-to-entry segments provide stable, recurring revenue from specialized patient groups. |
| Geographic Exposure (Global) | Includes revenue from US, Japan, Europe, and emerging markets. | Diversification across regions helps mitigate country-specific regulatory or economic risks. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-10-29 | When Before Market | Estimate 0.31 | Actual - |
Profitability
Profit Margin -3.54% | Operating Margin (TTM) 16.45% |
Management Effectiveness
Return on Assets (TTM) 2.69% | Return on Equity (TTM) -2.26% |
Valuation
Trailing PE - | Forward PE 12.38 | Enterprise Value 93.80B | Price to Sales(TTM) 0.01 |
Enterprise Value 93.80B | Price to Sales(TTM) 0.01 | ||
Enterprise Value to Revenue 3.19 | Enterprise Value to EBITDA 25.05 | Shares Outstanding 3.19B | Shares Floating 3.16B |
Shares Outstanding 3.19B | Shares Floating 3.16B | ||
Percent Insiders 0.08 | Percent Institutions 3.31 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.